75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 75070 - Statement - Condensed Consolidated Statements of Cash Flows 2 link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - License, Collaboration and Other Agreements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Considered for Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Significant Expense Categories Reviewed By CODM (Details) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Fair Value Measurements - Schedule of Available-for-sale Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - License, Collaboration and Other Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Facility Lease and Reconciliation to Operating Lease Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Facility Lease and Reconciliation to Operating Lease Liability (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Financing Lease and Reconciliation to Financing Lease Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Financing Lease and Reconciliation to Financing Lease Liability (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Stockholders' Equity - Summary of Assumptions Used to Determine Fair Value of Employee Stock Option Grants and Performance Options with Market Condition (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Stockholders' Equity - Schedule of Allocation of Stock-Based Compensation for All Options and Restricted Stock Units and Stock Issued Pursuant to Our Employee Stock Purchase Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Common Stock, Value, Subscriptions Agreed upon value of sale of common stock per transaction Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Canceled/forfeited/expired Issuance of common stock upon exercise of options and release of restricted stock units share. Issuance Of Common Stock Upon Exercise Of Options And Release Of Restricted Stock Units Share Issuance of common stock upon release of restricted stock units, Shares Common stock options and restricted stock units. Common Stock Options And Restricted Stock Units [Member] Common Stock Options and Restricted Stock Units [Member] Finance Lease, Liability Present value of lease payments Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Finance Lease, Liability, to be Paid, Year Four 2028 Preferred Stock, Shares Issued Preferred stock, shares issued Statement of Financial Position Location, Balance [Domain] Balance Sheet Location Plan Name [Axis] Plan Name Research and development expenses: Research and Development Expense [Abstract] Equity [Abstract] Entity Current Reporting Status Entity Current Reporting Status Municipal Bonds [Member] Municipal Bonds [Member] Operating Expenses [Abstract] Operating expenses: Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Shares Authorized Common stock, shares authorized Common Stock Value Subscriptions Sales Made Prior to Amendment Common stock value subscriptions sales made prior to amendment. Common stock value subscriptions sales made prior to amendment Product and Service [Axis] Product and Service Document Fiscal Period Focus Document Fiscal Period Focus Finance Lease, Liability [Abstract] Revenue from Contract with Customer [Abstract] Revenues: Entity Shell Company Entity Shell Company Segment Reporting Segment Reporting, Policy [Policy Text Block] Cash and Cash Equivalent Cash and cash equivalents at the end of period Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Common Stock, Shares, Issued Common stock, shares issued Asset Class [Domain] Asset Class Statement [Table] Statement [Table] Restricted Cash, Noncurrent Restricted cash at the end of period Restricted cash Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for lease obligation Warrants for common stock. Warrants For Common Stock [Member] Common Stock Warrants [Member] Common Stock Warrants [Member] Statement [Line Items] Statement [Line Items] Proceeds from issuance of common stock through underwritten follow on offering net of offering costs. Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs Proceeds from issuance of common stock from underwritten follow-on public offering, net of offering costs Loss Contingency, Lawsuit Filing Date Loss contingency, lawsuit filing date Entity Filer Category Entity Filer Category Schedule of common stock reserved for future issuance. Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Summary of Common Stock Reserved for Future Issuance Liabilities and Equity Total liabilities and stockholders’ equity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Options Exercisable, Ending Balance Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset 2027 Finance Lease, Liability, to be Paid, Year Three License and Collaboration Revenues. License and Collaboration Revenues [Member] Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Efzofitimod Research and Development Expenses Efzofitimod research and development expenses. Efzofitimod expenses Shares issued, price per share Shares Issued, Price Per Share Shares Issued, Price Per Share Subsequent Event [Line Items] Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference Employee Stock Option [Member] 2026 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Commitments and contingencies disclosure. Commitments and Contingencies Disclosure [Table] Geographical [Domain] Geographical Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents and Restricted Cash Restricted Cash Liquidity and financial condition. Liquidity And Financial Condition Policy [Text Block] Liquidity and Financial Condition Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of Outstanding Stock Options, Granted Stock options granted Commission rate equal to gross proceeds. Commission Rate Equal To Gross Proceeds1 Commission Rate Equal To Gross Proceeds1 Increase (Decrease) in Other Receivables Other receivables Earnings Per Share, Basic Net loss per share - basic Net loss per share - basic Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Outstanding Stock Options, Ending Balance Number of Outstanding Stock Options, Beginning Balance Liabilities, Current Total current liabilities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Employee retention credit disclosure policy text block. Employee Retention Credit Disclosure [Policy Text Block] Employee Retention Credit Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Maturities of available-for-sale investment securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total Stockholders’ equity: Equity, Attributable to Parent [Abstract] Entity Small Business Entity Small Business Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Accumulated deficit Preferred Stock [Member] Preferred Stock Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Amendment Flag Amendment Flag Product and Service [Domain] Product and Service Share based compensation arrangement by share based payment award, equity instruments other than options, released in period, weighted average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Released Restricted Cash Member Restricted Cash Member Restricted Cash [Member] Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Risks And Uncertainties [Policy Text Block] Risks And Uncertainties Policy [Text Block] Risks and Uncertainties Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Increase (Decrease) in Operating Lease Liability Operating lease liability Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock [Member] Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false] Operating lease, lease not yet commenced, existence of option to extend Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Weighted average exercise price, granted 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Debt Securities, Available-for-Sale [Line Items] Schedule of Available-for-sale Securities [Line Items] Entity Address, Address Line One Entity Address, Address Line One Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Assumptions Used to Determine Fair Value of Employee Stock Option Grants and Performance Options with Market Condition Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Earnings Per Share [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Statement of Financial Position Location, Balance [Axis] Balance Sheet Location Operating Lease, Right-of-Use Asset Operating lease, right-of-use assets Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest, Total Net (gain) loss attributable to noncontrolling interest in Pangu BioPharma Limited Net loss attributable to noncontrolling interest in Pangu BioPharma Limited Payments to Acquire Debt Securities, Available-for-Sale Purchases of available-for-sale investment securities Motion to dismiss deadline date Motion to Dismiss Deadline Date Motion to dismiss deadline date. Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Subsidiary, Ownership Percentage, Parent Majority-owned subsidiary percentage Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Debt Securities, Available-for-Sale [Table Text Block] Schedule of Available-for-sale Investments Aggregate Amount Due Upon Achievement of Milestones Aggregate amount due upon achievement of milestones. Aggregate amount due upon achievement of milestones Investments, Debt and Equity Securities [Abstract] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net change in cash, cash equivalents and restricted cash Subsequent Event Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities not included in calculation of diluted net loss per share Anti-dilutive securities not considered for calculation of diluted net loss per share Common Stock, Par or Stated Value Per Share Common stock, par value Security Deposit Security deposit Operating Lease, Right-of-Use Asset, Periodic Reduction Amortization of right-of-use assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Contractual Term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Debt Securities, Available-for-Sale, Amortized Cost Gross Amortized Cost Debt Securities, Available-for-Sale Aggregate value of investment securities Debt Securities, Available-for-Sale, Total Market Value Debt Instruments [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, Shares Exercises Number of Outstanding Stock Options, Exercised Accrued Liabilities, Current Accrued expenses Accrued expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Ownership [Domain] Ownership Current Fiscal Year End Date Current Fiscal Year End Date Non-cash expenses (depreciation and stock-based compensation) Non-cash Research and Development Expenses Non-cash research and development expenses. Document Quarterly Report Entity Address, State or Province Entity Address, State or Province Jefferies LLC. Jefferies L L C [Member] Jefferies LLC [Member] Jefferies Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Outstanding Restricted Stock Units, Ending Balance Number of Outstanding Restricted Stock Units, Beginning Balance Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss attributable to aTyr Pharma, Inc. common stockholders Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Number of common stock shares reserved for issuance Geographical [Axis] Geographical Equity, Attributable to Noncontrolling Interest Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Noncontrolling interest in Pangu BioPharma Limited Stockholders' Equity Attributable to Noncontrolling Interest, Total Other General and Administrative Expense Other general and administrative expenses Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Subsequent Event [Member] Subsequent Events [Member] Other Assets, Noncurrent Other assets Debt Securities, Available-for-Sale, Current Available-for-sale investments Antidilutive Securities [Axis] Antidilutive Securities Revenue, Product and Service [Extensible Enumeration] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Options Vested and Expected to Vest Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Allocation of Stock-Based Compensation for All Options and Restricted Stock Units and Stock Issued Pursuant to Our Employee Stock Purchase Plan Available-for-Sale Securities [Member] Available-for-sale [Member] AOCI Attributable to Parent [Member] Other Comprehensive Gain/(Loss) [Member] Preferred Stock, Value, Issued Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2026 (unaudited) and December 31, 2025, respectively; no shares issued or outstanding as of March 31, 2026 (unaudited) and December 31, 2025 Minimum [Member] Minimum [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Financial Instrument [Axis] Financial Instrument Assets, Current [Abstract] Current assets: Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs Shares Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs Shares Issuance of common stock from underwritten follow-on public offering, net of offering costs, Shares Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) [Member] License agreement abstract. License Agreement [Abstract] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Assets Measured at Fair Value on Recurring Basis Liabilities, Current [Abstract] Current liabilities: 2030 and thereafter Lessee, operating lease, liability payments due after year four. Lessee, Operating Lease, Liability Payments Due After Year Four Shares, Outstanding Ending balance, Shares Beginning balance, Shares Commitments and Contingencies Commitments and contingencies (Note 4) Lessee, Leases [Policy Text Block] Leases Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Ending Balance Weighted Average Grant Date Fair Value, Beginning Balance Stockholders' Equity Shareholders' Equity and Share-Based Payments [Text Block] General and Administrative Expense [Member] General and Administrative Expense [Member] Operating Lease, Liability Present value of lease payments ATM offering program. A T M Offering Program [Member] ATM Offering Program [Member] Auditor Firm ID Auditor Firm ID Description of business. Description Of Business [Table] Description Of Business [Table] Finance Lease, Liability, Current Current portion of financing lease liability Less: Current portion of financing lease liability Finance Lease, Weighted Average Discount Rate, Percent Financing lease, weighted-average discount rate Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Consolidated net loss Consolidated net loss Consolidated net loss Net loss Weighted Average Number of Shares Outstanding, Basic Shares used in computing net loss per share, basic Weighted Average Number of Shares Outstanding, Basic, Total Scenario [Axis] Scenario Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Options Exercisable Leases, Operating [Abstract] Loss Contingency, Name of Defendant Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Milestone payment received. Milestone Payment Received Milestone payments received Subsequent Events Subsequent Events [Text Block] APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Equity, Attributable to Parent Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Total aTyr Pharma stockholders’ equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Basis of Accounting, Policy [Policy Text Block] Organization and Business Statement of Stockholders' Equity [Abstract] Lessee Operating Lease Liability Undiscounted Excess Interest Amount Lessee Operating Lease Liability Undiscounted Excess Interest Amount Less: Amount representing interest Use of Estimates, Policy [Policy Text Block] Use of Estimates Allowance of Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Fair Value Disclosures [Text Block] Fair Value Measurements Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Minimum Payments under Non-cancelable Financing Lease and Reconciliation to Financing Lease Liability Noncontrolling Interest [Member] Noncontrolling Interest [Member] Annual upward adjustments on base rate percentage. Annual Upward Adjustments on Base Rate Percentage Annual upward adjustments on base rate, percentage Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Other segment items Segment Reporting, Other Segment Item, Amount Other segment items Plan Name [Domain] Plan Name Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Summary of Assumptions Used to Determine Fair Value of Employee Stock Purchase Plan Agreement termination notice period Agreement Termination Notice Period Agreement termination notice period. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2027 Finance Lease, Liability, to be Paid, Year One Non-cash expenses (depreciation and stock-based compensation) Non-Cash Expenses Related to General And Administrative Expenses Non-cash expenses related to general and administrative expenses. Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Kyorin pharmaceutical co ltd . Kyorin Pharmaceutical Co Ltd [Member] Kyorin Pharmaceutical Co Ltd [Member] Counterparty Name [Axis] Counterparty Name Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of Outstanding Stock Options, Vested and Expected to Vest, Ending Balance Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Sanjay S. Shukla [Member] Sanjay S. Shukla [Member] Interest Paid, Excluding Capitalized Interest, Operating Activity Interest paid Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Statistical Measurement [Domain] Statistical Measurement Assets, Current Total current assets Share-Based Payment Arrangement, Expense Stock-based compensation Total stock-based compensation expense Document Period End Date Document Period End Date Purchases of property and equipment in accounts payable. Purchases of Property and Equipment in Accounts Payable Purchases of property and equipment in accounts payable Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of Outstanding Stock Options, Exercisable, Ending Balance Development regulatory and sales milestone member. Development Regulatory And Sales Milestone [Member] Development Regulatory And Sales Milestones [Member] Statement of Financial Position [Abstract] Restricted Stock Units (RSUs) [Member] Restricted Stock Unit [Member] Revenue [Policy Text Block] Revenue Recognition Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Class of Stock [Axis] Class of Stock Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Available-for-sale, investments in unrealized loss positions, number of positions Less: Amount representing interest Finance Lease Liability Undiscounted Excess Interest Amount Finance lease liability undiscounted excess interest amount. Financial Instruments [Domain] Financial Instruments Commitments and contingencies disclosure. Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Weighted Average Number of Shares Outstanding, Diluted Shares used in computing net loss per share, diluted Weighted Average Number of Shares Outstanding, Diluted, Total Entity File Number Entity File Number OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Change in unrealized loss on available-for-sale investments, net of tax Net unrealized loss on investments, net of tax Cover [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of Outstanding Restricted Stock Units, Cancelled Scenario [Domain] Scenario Number of Operating Segments Number of operating segment Sale of Stock [Domain] Sale of Stock General and Administrative Expense General and administrative Total general and administrative expenses Research and Development Arrangement, Contract to Perform for Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Number of Outstanding Stock Options, Canceled/forfeited/expired Subsequent Event [Table] Operating Lease, Expense Operating lease expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Options Vested and Expected to Vest, Ending Balance New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Rule 10B5-1 Trading Arrangement Plan [Member] Rule 10B5-1 Trading Arrangement Plan [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Ownership [Axis] Ownership Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Investment, Type [Extensible Enumeration] Other Receivables, Net, Current Other receivables Other Receivables, Net, Current, Total Operating lease, term of lease Lessee, Operating Lease, Term of Contract Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Operating Lease, Liability, Current Current portion of operating lease liability Less: Current portion of operating lease liability Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Depreciation expense Document Transition Report Document Transition Report Operating Expenses Total operating expenses Research and Development Expense Research and development Capitalization of R&D costs Total research and development expenses Convertible Preferred Stock [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Litigation Status [Axis] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss Statement of Cash Flows [Abstract] HONG KONG Hong Kong [Member] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Base rent per square foot Base Rent Per Square Foot Base rent per square foot Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Restricted Stock Units Activity Net loss attributable to aTyr Pharma, Inc. Net loss attributable to aTyr Pharma, Inc. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Assets [Abstract] Assets Description of business. Description Of Business [Line Items] Description Of Business [Line Items] Entire disclosure of license, collaboration and other agreements. License Collaboration And Other Agreements [Text Block] License, Collaboration and Other Agreements Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Document Fiscal Year Focus Document Fiscal Year Focus Two thousand fifteen stock plan. Two Thousand Fifteen Stock Plan [Member] Shares Available Under the 2015 Plan [Member] Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities: Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Research and Development Expense [Member] Research and Development Expense [Member] Pending Litigation [Member] Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs Issuance of common stock from underwritten follow-on public offering, net of offering costs Share-Based Payment Arrangement [Abstract] Assets, Fair Value Disclosure Total assets measured at fair value Sale of Stock [Axis] Sale of Stock Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by (used in) investing activities Finance Lease, Weighted Average Remaining Lease Term Financing lease, weighted-average remaining lease term Title of 12(b) Security Title of 12(b) Security Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Cancelled Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend Operating lease, lease not yet commenced, option to extend Proceeds from issuance of common stock through at market offering net of offering costs. Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs Proceeds from issuance of common stock from at-the-market offerings, net of offering costs 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Right-of-Use Asset, after Accumulated Amortization Financing lease, right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Beginning Balance Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total Proceeds from issuance of common stock through option exercises Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Measurement Frequency [Domain] Measurement Frequency Statement of Income Location, Balance [Axis] Income Statement Location Trading Symbol Trading Symbol Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating lease. Schedule Of Future Minimum Rental Payments For Operating Lease Table [Text Block] Schedule of Future Minimum Payments under Non-cancelable Operating Lease and Reconciliation to Operating Lease Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Subsequent Event Type [Axis] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows from financing activities: Lessee, Finance Lease, Term of Contract Financing lease, term of contract Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Opposition Response Due Date Opposition response due date. Opposition response due date Fair Value, Recurring [Member] Fair Value, Measurements, Recurring [Member] Lessee operating lease, lease commencement date Lessee Operating Lease, Lease Commencement Date Lessee Operating Lease, Lease Commencement Date Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments Equity Components [Axis] Other Comprehensive Gain/(Loss) [Member] Stock issued during period shares at the market offerings net of offering costs. Stock Issued During Period Shares At The Market Offerings Net Of Offering Costs Issuance of common stock from at the market offerings, net of offering costs, Shares Nonoperating Income (Expense) Total other income (expense), net Nonoperating Income (Expense), Total Equity Component [Domain] Equity Component Asset Class [Axis] Asset Class Stock issued during period value at the market offerings net of offering costs. Stock Issued During Period Value At The Market Offerings Net Of Offering Costs Issuance of common stock from at-the-market offerings, net of offering costs Document Annual Report Document Annual Report Statement of Comprehensive Income [Abstract] Maximum [Member] Maximum [Member] Maximum [Member] Statistical Measurement Statistical Measurement [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Prepaid Expense, Current Prepaid expenses Prepaid Expense, Current, Total Common Stock, Value, Issued Common stock, $0.001 par value per share; 170,000,000 authorized shares as of March 31, 2026 (unaudited) and December 31, 2025, issued and outstanding shares -- 98,051,212 as of March 31, 2026 (unaudited) and 98,031,104 as of December 31, 2025 Property and Equipment [Member] Property, Plant and Equipment [Member] Finance Lease, Principal Payments Principal paid on finance lease liabilities Litigation Status [Domain] Consolidation, Policy [Policy Text Block] Principles of Consolidation Equity, Including Portion Attributable to Noncontrolling Interest Ending balance Beginning balance Total stockholders' equity Equipment [Member] Leased Equipment [Member] Additional License And Collaboration Agreement Revenue [Member] Additional license and collaboration agreement revenue Entity Public Float Entity Public Float Pangu BioPharma Limited. Pangu Bio Pharma Limited [Member] Pangu BioPharma [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Preferred Stock, Shares Authorized Preferred stock, shares authorized Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Comprehensive loss attributable to noncontrolling interest in Pangu BioPharma Limited Debt Security Category [Axis] Debt Security Category Employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Shares Available Under the Employee Stock Purchase Plan [Member] Employee Stock [Member] ESPP [Member] Entity Registrant Name Entity Registrant Name Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Entity Voluntary Filers Entity Voluntary Filers Share based compensation arrangement by share based payment award, equity instruments other than options, released in period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period Number of Outstanding Restricted Stock Units, Released Additional Paid in Capital, Total Additional Paid in Capital Additional paid-in capital Subsequent Events [Abstract] Accrued interest receivable on available-for-sale Debt Securities Available For Sale Accrued Interest Debt Securities Available For Sale Accrued Interest Measurement Frequency [Axis] Measurement Frequency Two thousand twenty two inducement plan. Two Thousand Twenty Two Inducement Plan [Member] Shares Available Under the 2022 Inducement Plan [Member] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of offering costs Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Outstanding Restricted Stock Units, Granted Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Contractual Term, Options Exercisable Income Statement [Abstract] Cash and cash equivalents restricted cash and available for sale investments. Cash And Cash Equivalents Restricted Cash And Available For Sale Investments Cash, cash equivalents, available-for-sale investments and restricted cash Upfront and milestone payments received Upfront and Milestone Payment Received Upfront and milestone payment received. Unaudited interim financial information. Unaudited Interim Financial Information Policy [Text Block] Unaudited Interim Financial Information Stock Issued During Period, Shares, New Issues Number of shares issued and sold Sales agreement. Sales Agreement [Member] Sale Agreement [Member] Net loss per share - diluted Net loss Per Share, Diluted Net loss per share - diluted Summary of Significant Expense Categories Reviewed by CODM Schedule of Segment Reporting Information, by Segment [Table Text Block] City Area Code City Area Code Auditor Name Auditor Name Finance Lease, Liability, Noncurrent Long-term financing lease liability, net of current portion Class X convertible preferred stock. Class X Convertible Preferred Stock [Member] Class X Convertible Preferred Stock [Member] Preclinical Development And Other Shared Research And Development Expense Preclinical Development And Other Shared Research And Development Expense Preclinical development and other shared research and development expenses Counterparty Name [Domain] Counterparty Name Operating Lease, Weighted Average Remaining Lease Term Operating lease, weighted average remaining lease term Debt commitments and contingencies. Debt Commitments And Contingencies [Text Block] Commitments and Contingencies Property, Plant and Equipment, Net Property and equipment, net Property and equipment, Net Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at the end of period Cash, cash equivalents and restricted cash at the end of period Operating Income (Loss) Loss from operations Retained Earnings [Member] Accumulated Deficit [Member] Operating Lease, Weighted Average Discount Rate, Percent Operating lease, weighted average discount rate Operating Lease, Liability, Noncurrent, Total Operating Lease, Liability, Noncurrent Long-term operating lease liability, net of current portion Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash (used in) provided by financing activities Auditor Location Auditor Location Available for sale securities effective maturity period. Available For Sale Securities Effective Maturity Period Available-for-sale investments effective maturity period Investments, Fair Value Disclosure Investments, fair value Investments, Fair Value Disclosure, Total Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Warrants Outstanding Loss Contingency, Name of Plaintiff Loss contingency, name of plaintiff Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Potentially Dilutive Securities Not Considered for Calculation of Diluted Net Loss Per Share Estimated Litigation Liability Estimated litigation liabillity Corporate Debt Securities [Member] Corporate Debt Securities [Member] Debt Securities, Available-for-Sale [Table] Entity Interactive Data Current Entity Interactive Data Current Research and Development, Contract to Perform for Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Increase (Decrease) in Contract with Customer, Liability Contract liability Statement of Income Location, Balance [Domain] Income Statement Location Accrued Expenses Accrued Expenses Policy [Text Block] accrued expenses. Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Operating lease, lease not yet commenced, extension term Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash flows from operating activities: License agreements and other agreements. License Agreements And Other Agreements [Text Block] License and Other Agreements Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount of available-for-sale investment securities Entity Tax Identification Number Entity Tax Identification Number Local Phone Number Local Phone Number Finance Lease, Liability, to be Paid, Year Two 2027 Accounting Policies [Abstract] Total revenues Revenue License and collabortion agreement revenues General and Administrative Expense [Abstract] General and administrative expenses: Class of Stock [Domain] Class of Stock Commercial Paper [Member] Commercial Paper [Member] Entity Emerging Growth Company Entity Emerging Growth Company Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Contractual Term, Options Vested and Expected to Vest Available for sale investments number of positions. Available for Sale Investments Number of Positions Available for sale investments number of positions Area of Land Lease space